216261US0CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

:

IN RE APPLICATION OF

DARIO CREMASCHI ET AL

: ATTN: APPLICATION BRANCH

SERIAL NO: New Application

FILED: HEREWITH

FOR: USE OF MICROPARTICLES

HAVING A PROTEIN AND AN

ANTIBODY ADSORBED

THEREON FOR PREPARING A

PHARMACEUTICAL COMPOSITION FOR INTRANASAL ADMINISTRATION

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE SPECIFICATION

Please amend the specification as follows:

Page 1, after the title on line 4, insert the following paragraph:

--The present application is a Continuation Application of U.S. Serial No. 09/402,474 filed November 18, 1999, which in turn is a National Stage Application under 35 U.S.C. § 371 of PCT/EP98/02214 filed April 8, 1998.--

IN THE CLAIMS

Please cancel Claims 1-10.

~, 3

Please add the following claims:

- 11. (New) A method for intranasally administering a composition comprising a microparticle having a protein and an antibody adsorbed thereon, wherein said administering comprises contacting a microparticle having a protein and an antibody thereon with the nasal mucosa of a patient in need thereof.
- 12. (New) The method of Claim 11, wherein said protein is selected from the group consisting of BSA, insulin, enkephalin, hormones, growth factors, cytokines, coagulation factors, polypeptides, and antimicrobial agents.
- 13. (New) The method of Claim 11, wherein said antibody is an immunoglobulin selected from the group consisting of IgM, IgA, and IgG.
- 14. (New) The method of Claim 13, wherein said immunoglobulin is specific for the protein.
 - 15. (New) The method of Claim 11, wherein said microparticle is biodegradable.
- 16. (New) The method of Claim 11, wherein said microparticle comprises polystyrene.
- 17. (New) The method of Claim 11, wherein the ratio of protein to antibody is 1 to 15,000 moles of protein per mole of antibody.
- 18. (New) The method of Claim 11, wherein the ratio of protein to antibody is 1 to 5,000 moles of protein per mole of antibody.
- 19. (New) The method of Claim 11, wherein the ratio of protein to antibody is 1 to 100 moles of protein per mole of antibody.

- 20. (New) A method for intranasally administering a composition comprising a microparticle and an antibody adsorbed thereon, wherein said administering comprises having a protein and an antibody thereon with the nasal mucosa of a patient in need thereof, and wherein the transepithelial transport obtained with 3.2×10^{11} microparticles/ml is $1.7^{\circ}/_{00}$.
- 21. (New) The method of Claim 20, wherein said protein is selected from the group consisting of BSA, insulin, enkephalin, hormones, growth factors, cytokines, coagulation factors, polypeptides, antimicrobial agents.
- 22. (New) The method of Claim 20, wherein said antibody is an immunoglobulin selected from the group consisting of IgM, IgA, and IgG.
- 23. (New) The method of Claim 22, wherein said immunoglobulin is specific for the protein.
 - 24. (New) The method of Claim 20, wherein said microparticle is biodegradable.
- 25. (New) The method of Claim 20, wherein said microparticle comprises polystyrene.
- 26. (New) The method of Claim 20, wherein the ratio of protein to antibody is 1 to 15,000 moles of protein per mole of antibody.
- 27. (New) The method of Claim 20, wherein the ratio of protein to antibody is 1 to 5,000 moles of protein per mole of antibody.
- 28. (New) The method of Claim 20, wherein the ratio of protein to antibody is 1 to 100 moles of protein per mole of antibody.--

REMARKS

Claims 11-28 are active in the present application. Support for Claims 11-28 are found in Claims 1-11 and in the specification as originally filed. No new matter is added.

Applicants submit that the present application is ready for examination on the merits.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618

Daniel J. Pereira, Ph.D. Registration No. 45,518

eg2 →

22850

703) 413-3000

Fax #: (703) 413-2220

NFO:DJP

I:\user\DJPER\216261US0CONT-pr.wpd

Marked-Up Copy
Serial No.: New U.S.
Application
Amendment Filed: Herewith

IN THE CLAIMS

Claims 11-28 (New)